vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and VIRTUS INVESTMENT PARTNERS, INC. (VRTS). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $199.5M, roughly 1.2× VIRTUS INVESTMENT PARTNERS, INC.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 3.6%, a 7.6% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -4.1%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -5.7%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
VIRTUS INVESTMENT PARTNERS, INC.VRTSEarnings & Financial Report
Virtus Investment Partners, Inc. is an American company which operates as a multi-manager asset management business, comprising a number of individual affiliated managers, each having its own investment process and brand, and the services of unaffiliated sub advisers.
ANIP vs VRTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $199.5M |
| Net Profit | $27.5M | $7.1M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 7.7% |
| Net Margin | 11.1% | 3.6% |
| Revenue YoY | 29.6% | -4.1% |
| Net Profit YoY | 367.5% | -78.1% |
| EPS (diluted) | $1.14 | $1.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $199.5M | ||
| Q4 25 | $247.1M | $208.0M | ||
| Q3 25 | $227.8M | $216.4M | ||
| Q2 25 | $211.4M | $210.5M | ||
| Q1 25 | $197.1M | $217.9M | ||
| Q4 24 | $190.6M | $233.5M | ||
| Q3 24 | $148.3M | $227.0M | ||
| Q2 24 | $138.0M | $224.4M |
| Q1 26 | — | $7.1M | ||
| Q4 25 | $27.5M | $33.9M | ||
| Q3 25 | $26.6M | $31.3M | ||
| Q2 25 | $8.5M | $42.7M | ||
| Q1 25 | $15.7M | $28.1M | ||
| Q4 24 | $-10.3M | $39.5M | ||
| Q3 24 | $-24.2M | $49.1M | ||
| Q2 24 | $-2.3M | $26.0M |
| Q1 26 | — | 7.7% | ||
| Q4 25 | 14.1% | 19.1% | ||
| Q3 25 | 15.9% | 21.7% | ||
| Q2 25 | 6.6% | 21.5% | ||
| Q1 25 | 13.3% | 16.8% | ||
| Q4 24 | -2.3% | 21.7% | ||
| Q3 24 | -13.8% | 24.3% | ||
| Q2 24 | 3.7% | 19.7% |
| Q1 26 | — | 3.6% | ||
| Q4 25 | 11.1% | 16.3% | ||
| Q3 25 | 11.7% | 14.5% | ||
| Q2 25 | 4.0% | 20.3% | ||
| Q1 25 | 8.0% | 12.9% | ||
| Q4 24 | -5.4% | 16.9% | ||
| Q3 24 | -16.3% | 21.6% | ||
| Q2 24 | -1.7% | 11.6% |
| Q1 26 | — | $1.05 | ||
| Q4 25 | $1.14 | $5.15 | ||
| Q3 25 | $1.13 | $4.65 | ||
| Q2 25 | $0.36 | $6.12 | ||
| Q1 25 | $0.69 | $4.05 | ||
| Q4 24 | $-0.45 | $4.65 | ||
| Q3 24 | $-1.27 | $5.71 | ||
| Q2 24 | $-0.14 | $2.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $136.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $93.6B |
| Total Assets | $1.4B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $136.6M | ||
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $390.0M | ||
| Q3 25 | — | $390.6M | ||
| Q2 25 | — | $231.3M | ||
| Q1 25 | — | $231.7M | ||
| Q4 24 | — | $232.1M | ||
| Q3 24 | — | $237.5M | ||
| Q2 24 | — | $247.6M |
| Q1 26 | — | $93.6B | ||
| Q4 25 | $540.7M | $934.0M | ||
| Q3 25 | $505.8M | $918.7M | ||
| Q2 25 | $436.8M | $896.4M | ||
| Q1 25 | $418.6M | $893.7M | ||
| Q4 24 | $403.7M | $897.5M | ||
| Q3 24 | $405.9M | $889.0M | ||
| Q2 24 | $455.8M | $868.7M |
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $4.3B | ||
| Q3 25 | $1.4B | $3.9B | ||
| Q2 25 | $1.3B | $3.7B | ||
| Q1 25 | $1.3B | $3.7B | ||
| Q4 24 | $1.3B | $4.0B | ||
| Q3 24 | $1.3B | $3.6B | ||
| Q2 24 | $920.8M | $3.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | 0.43× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | — | 0.26× | ||
| Q4 24 | — | 0.26× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $-67.2M | ||
| Q3 25 | $44.1M | $108.3M | ||
| Q2 25 | $75.8M | $75.8M | ||
| Q1 25 | $35.0M | $-3.8M | ||
| Q4 24 | $15.9M | $1.8M | ||
| Q3 24 | $12.5M | $69.1M | ||
| Q2 24 | $17.4M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $-74.1M | ||
| Q3 25 | $38.0M | $106.9M | ||
| Q2 25 | $71.8M | $74.2M | ||
| Q1 25 | $32.5M | $-6.8M | ||
| Q4 24 | $13.5M | $-3.8M | ||
| Q3 24 | $7.7M | $68.7M | ||
| Q2 24 | $13.0M | $68.6M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | -35.6% | ||
| Q3 25 | 16.7% | 49.4% | ||
| Q2 25 | 34.0% | 35.2% | ||
| Q1 25 | 16.5% | -3.1% | ||
| Q4 24 | 7.1% | -1.6% | ||
| Q3 24 | 5.2% | 30.3% | ||
| Q2 24 | 9.4% | 30.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 3.3% | ||
| Q3 25 | 2.7% | 0.7% | ||
| Q2 25 | 1.9% | 0.7% | ||
| Q1 25 | 1.3% | 1.4% | ||
| Q4 24 | 1.3% | 2.4% | ||
| Q3 24 | 3.2% | 0.2% | ||
| Q2 24 | 3.2% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | -1.99× | ||
| Q3 25 | 1.66× | 3.45× | ||
| Q2 25 | 8.87× | 1.77× | ||
| Q1 25 | 2.23× | -0.13× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | — | 2.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
VRTS
| Investment management fees | $169.1M | 85% |
| Administration and shareholder service fees | $17.3M | 9% |
| Distribution and service fees | $11.6M | 6% |
